In conclusion, we have developed a CTLA4-PD-L1 chimeric protein vaccine, which may function both as a therapeutic cancer vaccine and as a preventive cancer vaccine in the TAA-induced iCCA rat model. This evidence concerns the gene CTLA4 and infantile convulsions and choreoathetosis.